

Braizon Therapeutics ,Inc. advances into the Hello Tomorrow Challenge 2022 Global Summit!



With all finalists of Hello Tomorrow Asia Pacific 2022 / Hello Tomorrow Japan

On October 5th, 2022, the Hello Tomorrow APAC held its 2022 SUMMIT in Singapore. Dr. Philip Davy, President and CEO of Braizon Therapeutics ,Inc. took part in the event as one of the finalists of the Hello Tomorrow APAC challenge

Braizon Therapeutics ,Inc. located in KING SKYFRONT, was the Grand Winner out of fifteen finalists, winning their ticket to become finalist of the Hello Tomorrow Global Challenge in Paris, on March 2023.

Braizon Therapeutics ,Inc. is a start-up aiming for applying and commercializing "breakthrough technology for drug delivery to the brain."

It is the result of the joint research between Professor KATAOKA Kazunori, Graduate Schools of Engineering and Medicine, University of Tokyo (Currently Professor Emeritus at The University of Tokyo), and Professor YOKOTA Takahiro, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, medical and life science fields.

For treating CNS diseases, drugs need to be delivered to the brain, however as the brain has a biological barrier, it is extremely difficult to deliver drugs as necessary amount of treatment. The solution "Brain Access" is trying to solve this problem by using transferrin receptor ligand-modified micelles. Moreover, the technology is uniquely versatile; adapting to various forms of drugs, low molecular weight compounds, nucleic acid drugs, etc. It demonstrates high delivery efficiency relative to dosage and thus expectations for commercialization are high.

Hello Tomorrow is a Paris-based organization with an extensive global network in deep tech, 6 hubs worldwide, including Japan and Singapore, and more than 70 individuals in 30+ countries. They support early-stage deep tech entrepreneurs with impactful and disruptive technologies. They also promote social implementation of solutions and innovative technologies for the modern society through R&D.

Braizon Therapeutics applied to the Hello Tomorrow Japan

Challenge 2022, a pitch contest in English targeting Japan based startups, and held in Japan on September 13th, winning their fast track for the Hello Tomorrow APAC Challenge 2022.

The Hello Tomorrow Global Summit, one of the largest deep tech events, is scheduled to be held from March 9th to 10th, 2023, in Paris. Withing the Global Summit is held the Hello Tomorrow Global Challenge, one of the world's most renowned early-stage deep tech startups pitch contests. Every year, more than 4000 startups from 115 countries apply. Around 800 of them are selected as Deep Tech Pioneers, assessing the quality and impact of their technology. Around 80 startups are selected to become finalists of the Global Challenge.

The winners of the Global Challenge will win an equity-free prize money: €100K for the Grand Winner, €30K for 2nd place and €20K for 3rd place. The 10 Track Winners will also receive in-kind prizes in the form of customized coaching sessions provided by experts, and personal introductions with relevant investors and potential partners and clients.

It is certain that Braizon Therapeutics' technology will catch attention! Approximately 1,000 startups developing cutting-edge technologies and over three hundred deep technology investors and other active players involved in Deep Tech are gathered. Your support is very much appreciated. Thank you!



Braizon Therapeutics Co / Hello Tomorrow APAC Challenge 2022

[Click here for Hello Tomorrow Global Challenge](#)

Visit by Economic and Commercial Office, Embassy of Spain and Spanish companies

On October 11th, Economic and Commercial Office, Embassy of Spain and Spanish companies visited KING SKYFRONT. The purpose of their visit was to observe the current situation of a life-science, innovation eco-system in Japan and get a hint for business collaboration with Japan through interaction with local institutions.

At the Innovation Center of NanoMedicine (iCONM), where they visited first, they had a summary from Deputy Director Dr. Nagai about the efforts for building an "In-body hospitals" by creating virus-sized smart machines. Afterwards, they toured the facilities, focusing on the distinctive areas that have been developed for the creation of open innovation.

At the National Institute of Health Sciences (NIHS), Dr. Homma, Deputy Director General, introduced the history of NIHS and current efforts in regulatory science for pharmaceuticals, foods, and chemicals in living environment. Dr. Yamamoto, Director of Division of Medical Devices, Dr. Sato, Director of Division of Cell-Based Therapeutic Products, Dr. Kondo, Director of Division of Biochemistry and Dr. Kanda, Director of Division of Pharmacology introduced specific research outlines. These presentations were very interesting.



First clinical trial of products developed by Gene Therapy Research Institution Co., Ltd. In Japan starts

On October 17th, 2022, Gene therapy Research Institution Co., Ltd. announced their developed GT0002X targeting Parkinson's disease was administrated to the patients at Jichi Medical University Hospital.

Aiming to improve long-term symptoms, this clinical trial stimulates the release of dopamine using a virus that is harmless to the human body to send genes to targeted areas in the brain. Going forward, they plan to administrate the drug to twelve patients at a rate of about one patient per month and follow-up to investigate its safety and efficacy, with the aim of approving it as a new treatment method.

【Deadline Dec.9】 Cell culture training for "Monozukuri" companies

In life-science field, along with development of technology and diversity in R&D, a new development of culture devices, equipment, and use of technologies from different field are anticipated.

To facilitate this cell culture training will be held for "Monozukuri" companies who are interested in the life sciences field. It is an opportunity to understand how their technology can be applied to the development needs of cell culture.

The presenters will be Kanagawa Prefecture who developed the Life Innovation Center which is a core center of industrialization of regenerative medicine & cell therapy at KINGS SKYFRONT and Biotech Lab. which operates an open laboratory, Osaka Sanitary who conducts R&D and TONOMACHI Life Science Cluster Division. We look forward to seeing as many of you as possible at the training.

[Click here for the details of the training](#)

Hosted "Shared Labs Pitch! @ CIC x KING SKYFRONT

On September 21st, TONOMACHI Life Science Cluster Division jointly hosted a pitch event with CIC Tokyo, in which lab managers and life science start-ups joining shared labs presented and discussed the relationships between the shared lab managers and start-ups.

"iCONM in collaboration with BioLabs" and Braizon Therapeutics from KING SKYFRONT joined the event and talked about how shared lab works and what the advantages of the Innovation Center of NanoMedicine (iCONM) facilities are.

To build an innovation ecosystem in Japan, lab facilities for experiments in the life science field is attracting more attention.

In particular, the "shared labs" is highly attractive since start-ups can start their experiments at that day with a minimum investment, by sharing lab space and equipment. However, more shared labs are still required in Japan. In the last session of the event, panelists from start-ups and lab managers discussed how to create an innovation ecosystem from shared labs in a local area", and the discussion was involved with audiences and the event was very exciting.



Recruitment of users of the shared office

"TONOMACHI Connect"

If you are willing to have a base for your activities in KING SKYFRONT, please consider doing so.

We are now accepting applications for the KING SKYFRONT share office "Tonomachi Connect" located in the Research Gate Building II. Please consider if you are interested in having a base your activities in KING SKYFRONT.

From November, the opening hours will be extended to 10:00 pm on weekdays and 6:00 pm on Saturdays. (Closed on Sundays and public holidays)



For subscription

Keep you updated with the latest news from KING SKYFRONT

Please apply here for subscription. i-Newsletter comes out quarterly and free subscription.

<https://ws.formzu.net/fgen/S93679955/>

Date of issue: November 2022

Publisher: Kawasaki Institute of Industrial Promotion

Mail : info-ksfcl@kawasaki-net.ne.jp